Clinical Trials
30 trialsGNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Glycostem Therapeutics BV
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
CAR-T
Shenzhen University General Hospital
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Maxinovel Pty., Ltd.
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
Affiliated Hospital to Academy of Military Medical Sciences
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Kecellitics Biotech Company Ltd
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Southwest Hospital, China
A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Southwest Hospital, China
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Southwest Hospital, China
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
Shanghai Tongji Hospital, Tongji University School of Medicine
IM19CAR-T
Beijing Immunochina Medical Science & Technology Co., Ltd.
IDPR-HSCT
Peking University People's Hospital
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
Shanghai GeneChem Co., Ltd.
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Ann & Robert H Lurie Children's Hospital of Chicago
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.
Maria Sklodowska-Curie National Research Institute of Oncology
AML-14A
European Organisation for Research and Treatment of Cancer - EORTC